IMV INC.

IMV
Delayed Quote. Delayed  - 01/26 04:00:00 pm
4.51CAD -0.88%

IMV : Corporate Presentation

11/16/2020 | 09:43am

Investor Presentation

November 2020

1

Developing a New Class of Immunotherapies and Vaccines

We are committed to making immunotherapy and vaccines more effective, more broadly applicable, and more widely available to patients.

TICKER

IMV (Nasdaq & TSX)

MARKET CAP (Nov.11)

  • $US 270 M /
  • $CAD 353 M

Cash and cash equiv. (Sept. 30): 54.7 M CDN$ / 40.9 M US $

OUTSTANDING SHARES (Nov.11)

Basic : 67.1M

Fully diluted : 71.6M

© 2020 IMV Inc. All rights reserved.

2

Investment Highlights

DPX™ delivery platform to create a novel class of vaccines and immunotherapies

Unique mechanism of action that generates targeted and sustained stimulation of immune system

Immune cell activation that can be maintained over an extended period with limited side effects

Clinically-demonstrated activity in solid / hematologic cancers as well as infectious diseases

DPX-Survivac, lead oncology program focused on unmet medical needs

Demonstrated tumor regression in solid and hematologic cancers

Excellent safety profile across all clinical Phase 1 and 2 studies (N=350)

DPX-COVID-19, our answer to the global pandemic

Designed to generate prolonged antiviral protection

Potential ability to serve an older / immunocompromised population

Fully synthetic formulation that allows rapid, cost-efficientscale-up manufacturing

Milestones

Additional phase 2 DPX Survivac combination clinical data in DLBCL at ASH (Dec. 6, 2020)

Update on DPX-Survivac/CPA in late-stage ovarian cancer (Dec. 3, 2020) and for the basket trial (Q1 2021)

Initiate DPX COVID-19 Phase 1/2 trial before year end 2020

© 2020 IMV Inc. All rights reserved.

3

Leadership Team with Strong Track Record in Drug Development

Frederic Ors, MSc, MBA

Marie-Eve Charrois, MA

Brittany Davison, CPA, CA

Chief Executive Officer

Vice President, Regulatory

Vice President, Finance

Affairs

Pierre Labbé, CPA

Stephan Fiset, MSc, MBA

Ryan Marshall, MSc

Chief Financial Officer

Vice-President, Clinical

Vice President, Project

Research

Management and Operations

Andrew Hall

Tariq Massad, PhD, PMP

Marianne Stanford, PhD

Chief Business Officer

Vice President, Process Dev

Vice-President, Research &

and Manufacturing

Development

Joanne Schindler, DVM, MD

Annie Tanguay, BSc

Chief Medical Officer

Senior Vice President,

Quality and Regulatory

© 2020 IMV Inc. All rights reserved.

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

IMV Inc. published this content on 16 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2020 14:42:08 UTC

© Publicnow 2021
Copier lien
All news about IMV INC.
01/04
12/29
12/29
12/28
12/28